Chemical compound
Furazabol Trade names Frazalon, Miotalon, Qu Zhi Shu Other names Androfurazanol; DH-245; Furazalon; Frazalon; Pirzalon; 17α-Methyl-5α-androsta[2,3-c ]furazan-17β-ol; 17β-Hydroxy-17α-methyl-5α-androstano[2,3-c ]-1',2',5'-oxadiazole; 17α-Methyl-5α-androstano[2,3-c ][1,2,5]oxadiazol-17β-ol Routes of administration By mouth Drug class Androgen ; Anabolic steroid ATC code Legal status
Elimination half-life 4 hours[citation needed ] Excretion Urine
(1S ,2S ,10S ,13R ,14S ,17S ,18S )-2,17,18-Trimethyl-6-oxa-5,7-diazapentacyclo[11.7.0.02,10 .04,8 .014,18 ]icosa-4,7-dien-17-ol
CAS Number PubChem CID DrugBank ChemSpider UNII ChEMBL CompTox Dashboard (EPA ) ECHA InfoCard 100.013.621 Formula C 20 H 30 N 2 O 2 Molar mass 330.472 g·mol−1 3D model (JSmol )
O[C@@]5([C@@]4([C@H]([C@H]3[C@@H]([C@]2(Cc1nonc1C[C@@H]2CC3)C)CC4)CC5)C)C
InChI=1S/C20H30N2O2/c1-18-11-17-16(21-24-22-17)10-12(18)4-5-13-14(18)6-8-19(2)15(13)7-9-20(19,3)23/h12-15,23H,4-11H2,1-3H3/t12-,13+,14-,15-,18-,19-,20-/m0/s1
Y Key:RGLLOUBXMOGLDQ-IVEVATEUSA-N
Y
N Y (what is this?) (verify)
Furazabol (INN Tooltip International Nonproprietary Name , JAN Tooltip Japanese Accepted Name ) (brand names Frazalon , Miotalon , Qu Zhi Shu ), also known as androfurazanol , is a synthetic , orally active anabolic-androgenic steroid which has been marketed in Japan since 1969.[ 1] [ 2] [ 3] [ 4] It is a 17α-alkylated derivative of dihydrotestosterone (DHT) and is closely related structurally to stanozolol , differing from it only by having a furazan ring system instead of pyrazole .[ 5] Furazabol has a relatively high ratio of anabolic to androgenic activity.[ 4] As with other 17α-alkylated AAS, it may have a risk of hepatotoxicity .[ 6] The drug has been described as an antihyperlipidemic and is claimed to be useful in the treatment of atherosclerosis and hypercholesterolemia ,[ 5] but according to William Llewellyn, such properties of furazabol are a myth.[ 7]
^ J. Elks (14 November 2014). The Dictionary of Drugs: Chemical Data: Chemical Data, Structures and Bibliographies . Springer. pp. 585–. ISBN 978-1-4757-2085-3 .
^ Index Nominum 2000: International Drug Directory . Taylor & Francis. 2000. pp. 475–. ISBN 978-3-88763-075-1 .
^ William Andrew Publishing (22 October 2013). Pharmaceutical Manufacturing Encyclopedia, 3rd Edition . Elsevier. pp. 1725–. ISBN 978-0-8155-1856-3 .
^ a b Progress in Medicinal Chemistry . Elsevier. 1 January 1979. pp. 62–63. ISBN 978-0-08-086264-4 .
^ a b Fragkaki AG, Angelis YS, Koupparis M, Tsantili-Kakoulidou A, Kokotos G, Georgakopoulos C (2009). "Structural characteristics of anabolic androgenic steroids contributing to binding to the androgen receptor and to their anabolic and androgenic activities. Applied modifications in the steroidal structure". Steroids . 74 (2): 172–97. doi :10.1016/j.steroids.2008.10.016 . PMID 19028512 . S2CID 41356223 .
^ Abbate V, Kicman AT, Evans-Brown M, McVeigh J, Cowan DA, Wilson C, Coles SJ, Walker CJ (2015). "Anabolic steroids detected in bodybuilding dietary supplements - a significant risk to public health". Drug Test Anal . 7 (7): 609–18. doi :10.1002/dta.1728 . PMID 25284752 .
^ William Llewellyn (2007). Anabolics 2007: Anabolic Steroids Reference Manual . Body of Science. ISBN 978-0967930466 .